Anna Van Acker has over 25 years of wide-ranging experience at Merck. Ms. Van Acker is dedicated to the optimization of Merck’s product portfolio and marketing strategies on an international scale and strives to ensure access to innovative drugs. She has also worked tirelessly with governments and other organizations to support the improvement of key national health indicators in Europe, Asia and the Americas throughout the years.
Ms. Van Acker is a member of the Board of Directors of Montréal InVivo, an active member of the CEO Steering Council of Innovative Medicines Canada (IMC) and the Chair of the Private Payers Core Team at IMC.
A Belgian national, Ms. Van Acker holds a master’s degree in literature, linguistics and communications, as well as a post-graduate degree in marketing. She also studied leadership at Wharton (2013) and at Harvard (2015).